Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today highlighted new data on VYKATTM XR (diazoxide ...

FDA approval of VYKAT XR for hyperphagia in Prader-Willi Syndrome marks a major milestone for Soleno Therapeutics.

Disease name: Prader-Willi syndrome. Affected populations: This genetic, multisystem disorder affects an estimated 1 in 30,000 to 1 in 10,000 people worldwide.

Within the family program agenda, Aardvark’s Chief Medical Officer, Manasi Jaiman, M.D., will join a panel of clinicians to discuss the details of the company’s ongoing Phase 3 HERO study.

A new drug is helping families who've spent years padlocking fridges, chaining garbage cans, and hiding food as their ...

Prader-Willi syndrome (PWS) is a rare genetic disease that causes a wide range of physical, mental and behavioral problems, most notably a constant sense of hunger. PWS has a birth incidence of 1 in ...

Soleno Therapeutics will present research on Prader-Willi syndrome at the upcoming International PWS ... community engagement and improving the lives of those affected by rare diseases like PWS.

Soleno Therapeutics, Inc. (NASDAQ:SLNO) focuses on rare diseases, particularly PWS hyperphagia. This condition creates insatiable hunger in patients, severely affecting their quality of life.

The Food and Drug Administration on Wednesday approved the first medicine to treat people with Prader-Willi syndrome, a rare genetic disease that causes an insatiable desire to eat.

Disease name: Prader-Willi syndrome. Affected populations: This genetic, multisystem disorder affects an estimated 1 in 30,000 to 1 in 10,000 people worldwide.